Related Experiment Video
Updated: Jul 6, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Improving outcomes in patients with advanced renal cell carcinoma
1Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232, USA. jeff.sosman@vanderbilt.edu
Abstract:
The emergence of targeted therapies for advanced renal cell carcinoma has been a dramatic turning point in improving outcomes for the majority of patients with this disease. In study populations comprising primarily good- and intermediate-risk patients with clear cell renal cell carcinoma and prior nephrectomy, prolonged progression-free survival was demonstrated for three angiogenesis-targeted agents: sunitinib (compared with interferon [IFN]), bevacizumab plus IFN (vs IFN alone) and sorafenib (vs placebo in cytokine-refractory patients). As a first-line treatment for patients with multiple poor-risk factors, temsirolimus, which inhibits mTOR, has improved not only progression-free survival compared with IFN but, more importantly, overall survival. Further studies are needed to determine whether combinations and/or sequencing of these targeted agents can further improve outcomes.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Kidney Transplant III: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
